Reuters logo
BRIEF-Seattle Genetics, Astellas announce updated enfortumab vedotin phase 1 data in metastatic urothelial cancer ​
June 5, 2017 / 2:57 PM / 4 months ago

BRIEF-Seattle Genetics, Astellas announce updated enfortumab vedotin phase 1 data in metastatic urothelial cancer ​

June 5 (Reuters) - Astellas Pharma Inc:

* Trial evaluating enfortumab vedotin in combination with CPIs is also planned for later in the year​

* Cos this year plan to initiate registrational monotherapy phase 2 trial for locally advanced/ MUC patients previously treated with CPI therapy Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below